Using a cellular model of Alzheimer's disease (AD), researchers found that a small molecule with epigenetic action, M344, altered the expression of key neuroprotective and AD-related genes; in a mouse model of AD, administration of M344 at low doses prevented cognitive decline and resulted in learning and memory improvements in behavioral tests, suggesting the therapeutic potential of multi-targeting compounds in treating AD.
###
Article #17-07544: "M344 promotes nonamyloidogenic amyloid precursor protein processing while normalizing Alzheimer's disease genes and improving memory," by Claude-Henry Volmar et al.
MEDIA CONTACT: Claes Wahlestedt, University of Miami, FL; tel: 305-243-1367; e-mail: < cwahlestedt@med.miami.edu >
Proceedings of the National Academy of Sciences